Initially it was believed that COX-2 inhibitors were better because they were associated with fewer stomach problems. However, numerous reports of heart attacks and strokes have led the FDA to reassess the risks and benefits of COX-2 inhibitors in such a way that one of them has already been recalled (Viox) and Celecoxib still available, has serious warnings and a recommendation that it be indicated in low doses and for short term Flekosteel.
In the management of RA, antimalarial drugs such as hydroxychloroquine and sulfasalazine have also been used in combination with methotrexate. However, its action is slow since it may take weeks or months to see any benefit.
No comments:
Post a Comment